Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 194; no. 4; pp. 784 - 788
Main Authors Quach, Hang, Nooka, Ajay, Samoylova, Olga, Venner, Christopher P., Kim, Kihyun, Facon, Thierry, Spencer, Andrew, Usmani, Saad Z., Grosicki, Sebastian, Suzuki, Kenshi, Delimpasi, Sosana, Weisel, Katja, Obreja, Mihaela, Zahlten‐Kumeli, Anita, Mateos, Maria‐Victoria
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.08.2021
Subjects
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
cancer
clinical studies
clinical trials
Dexamethasone
Dexamethasone - therapeutic use
Hematology
Humans
Multiple myeloma
Multiple Myeloma - drug therapy
Neoplasm Recurrence, Local - drug therapy
Oligopeptides - therapeutic use
Treatment Outcome
clinical studies
multiple myeloma
cancer
clinical trials
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Correspondence-1
ObjectType-Feature-4
ObjectType-News-2
content type line 66
ObjectType-Article-3
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17541